Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Brought to you by

Regulus Therapeutics nets $48.3mm through initial public offering

Oct 2012

Executive Summary

Less than two months after filing its S-1, Regulus Therapeutics Inc. (single-stranded oligonucleotide therapeutics) has netted $48.3mm in its initial public offering of 12.9mm shares (including the overallotment) for $4. Last month, the company anticipated selling 4.6mm shares at $10-12.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By